The share of domestically produced medicines in Russia stands at 63%, and exceeds 80% in government procurement, Russian Minister of Industry and Trade Anton Alikhanov reported at a meeting attended by Russian President Vladimir Putin devoted to the results of the December “Direct Line.”
“The expansion of production capacity has enabled us to reach a 63% share of domestic medicines on the open market. As for the government procurement market, we cover more than 80% of the needs of the state healthcare system,” he said.
“In the list of essential and vital medicines, we produce 86% of all items, and two-thirds of them can be manufactured using Russian pharmaceutical substances,” the minister noted. He added that, in particular, vaccines against 11 out of 12 pathogens included in the national immunization schedule are produced domestically under a full-cycle manufacturing process.
According to Alikhanov, work continues on the development and production of missing vaccines. With the support of the Industrial Development Fund, the company Nanolek has launched production of a human papillomavirus (HPV) vaccine in the Kirov Region. In the near future, with state support, the pharmaceutical manufacturer will “implement a large-scale project to produce medicines against meningococcal infection and for the prevention of chickenpox,” the minister said.
“Domestic manufacturers supply the Ministry of Health with more than 80% of oncology drugs, including the most advanced targeted therapies—medicines based on monoclonal antibodies,” Alikhanov noted, citing Biocad as an example. The company has brought to market the world’s first drug for the treatment of ankylosing spondylitis.
At the same time, the minister emphasized that there is still “a great deal of work ahead” regarding domestic medicines for HIV and hepatitis, as well as insulin products, which account for “about half or slightly more” of total government procurement. “The necessary competencies already exist, but many of these medicines are protected by patents. Once those patents expire, we will be ready to promptly launch production at Russian facilities,” Alikhanov stressed.
Source: GxP-news, January 22, 2026.
